CI

Cigna GroupB

NYSE / Health Care Equipment & Services

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$335.00

+22.8% vs current

Most likely

Base case

45%

Probability

Target price

$315.00

+15.5% vs current

B-

Bear case

25%

Probability

Target price

$255.00

-6.5% vs current

AI sentiment snapshot

Latest data as of 2026-05-03

AI commentary

Primary-source support is solid because the April 30 8-K and earnings release clearly confirm a beat-and-raise quarter, and secondary coverage adds consensus-beat framing plus at least one post-print target increase. Even so, sentiment looks mixed rather than euphoric: Reuters-linked and other coverage highlighted PBM profit pressure and the ACA marketplace exit, and the May 1 anchor price of $282.90 sits below some pre-print reference prices in trusted coverage, implying the initial earnings upside did not translate into a clean rerating. Analyst-revision breadth is still incomplete at T+3, and the more relevant comparison set is managed-care and PBM peers such as ELV, UNH, and CVS rather than medtech names, so this remains a cautious post-earnings monitoring memo rather than a high-conviction upgrade.

RankAlpha Sentiment Codex - 2026-05-03

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-15catalystPost-Q1 beat-and-raise revision cycleMedium impact

The April 30 earnings release showed Q1 2026 revenue up 5% to $68.5B, adjusted income from operations of $7.79 per share, and full-year adjusted income from operations guidance raised to at least $30.35 per share; Reuters-linked coverage also framed the print as above estimates, and a May 2026 Mizuho note raised its price target to $330 from $325 while maintaining Outperform. [#8-K-2026-04-30]

2026-07-01eventJuly 1 CEO transition to Brian EvankoMedium impact

Cigna announced that David Cordani will retire as CEO effective July 1, 2026 and Brian Evanko will succeed him, with Cordani becoming executive chair; the transition creates a dated governance checkpoint for execution and investor messaging.

2026-07-30catalystSegment mix shift toward specialty growth while PBM pressure stabilizesHigh impact

Evernorth Specialty and Care Services grew adjusted revenue 6% and pre-tax operating income 20%, helped by strong specialty volume and more generic and biosimilar adoption, while Pharmacy Benefit Services revenue rose 11% but pre-tax income fell 28% on lower contributions from large client relationships; sustained improvement depends on specialty growth continuing to offset PBM pressure. [#8-K-2026-04-30]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-03 • Updated nightlySource: Internal modelMethodology